With each new . Avenue Herrmann-Debroux 54 Disclaimer. In 2021, it is estimated that 537 million people have diabetes, and this number is projected to reach 643 million by 2030, and 783 million by 2045. Reducing glycated haemoglobin has been proven to reduce the risk of these complications while early attainment of glycaemic goal can have a legacy effect in later life. In this 10th edition of the IDF Diabetes Atlas, the prevalence of diabetes is estimated for the year 2021 and projected to the years 2030 and 2045. 4). J Epidemiol Glob Health. Google Scholar. 906 Citations. https://doi.org/10.2337/dc20-2439. 2023;55: 101751. https://doi.org/10.1016/j.eclinm.2022.101751. 2021;23(1):24551. Subsequent meta-analyses including more studies confirmed that SGLT2 inhibitors reduced the risk of MACE by 10% (HR 0.90; 95%CI 0.85, 0.95) [47] and GLP-1 receptor agonists by 14% (HR 0.86, 95%CI 0.79, 0.94; p=0.006) [9]. The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Hur KY, Moon MK, Park JS, et al. UK Prospective Diabetes Study Group. In: StatPearls [Internet]. Diabetes Obes Metab. Factsheets with global and regional data from the IDF Diabetes Atlas 10th Edition are available for download below. GLP-1 receptor agonists and cardiorenal outcomes in type2 diabetes: an updated meta-analysis of eight CVOTs. MeSH Among overweight patients treated with metformin, there was also persistent risk reduction for any diabetes-related endpoint (21%, p=0.01), myocardial infarction (33%, p=0.005), and death from any cause (27%, p=0.002) [32]. After exclusion of patients with T1D, patients with T2D treated with insulin or injectable GLP-1 receptor agonists, and patients without information on medications, 62,512 patients with T2D enrolled between 2007 and 2019 were analysed. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. https://doi.org/10.1056/NEJMoa1407963. 8600 Rockville Pike Provided by the Springer Nature SharedIt content-sharing initiative, Over 10 million scientific documents at your fingertips, Not logged in A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials, https://doi.org/10.1038/s41574-022-00776-2, https://doi.org/10.2991/jegh.k.191028.001, https://doi.org/10.1007/s00125-019-05078-3, https://doi.org/10.1186/s12933-018-0728-6, https://doi.org/10.1186/s12933-021-01366-8, https://doi.org/10.1186/s12933-021-01386-4, https://idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html, https://doi.org/10.1007/s13340-020-00439-5, https://doi.org/10.1007/s13300-019-00733-9, https://doi.org/10.1371/journal.pone.0123116, https://doi.org/10.1111/j.1464-5491.2008.02581.x, https://doi.org/10.1007/s00125-011-2404-1, https://doi.org/10.2337/diacare.21.8.1271, https://doi.org/10.1016/j.molmet.2020.101102, https://doi.org/10.1016/S2213-8587(17)30327-3, https://doi.org/10.1016/j.kint.2020.08.012, https://doi.org/10.1016/S0140-6736(19)32131-2, https://doi.org/10.1016/j.ahj.2013.07.012, https://doi.org/10.1001/jamacardio.2020.4511, https://doi.org/10.1080/14740338.2021.1898585, https://doi.org/10.1016/S2213-8587(19)30068-3, https://doi.org/10.1016/j.eclinm.2022.101751, https://doi.org/10.1016/j.kint.2022.06.013, https://doi.org/10.1371/journal.pmed.1003367, https://www.who.int/publications/i/item/9789241565257, https://doi.org/10.1016/S0140-6736(20)32374-6, http://creativecommons.org/licenses/by-nc/4.0/. The International Diabetes Federation (IDF) is proud to launch the 10th edition of the IDF Diabetes Atlas. 2019;8(12):e012356. In ADVANCE, 37% of patients were enrolled from Asia, notably China. The site is secure. Meanwhile, results from ACCORD have emphasized the importance of individualized treatment that takes into consideration the risk-to-benefit ratio, especially in high-risk patients. The opinions expressed in the manuscript are those of the authors. C. Patterson, S. Karuranga, +4 authors G. Ogle Published 1 November 2019 Medicine Diabetes research and clinical practice View on PubMed This site needs JavaScript to work properly. Diabetes Care. First published in 2000, the IDF Diabetes Atlas is produced by IDF in collaboration with a committee of scientific experts from around the world. 2013;36(11):375965. 2021-06-18. Reprinted from Mol Metab, 46:101102, Nauck MA, Quast DR, Wefers J, Meier JJ; GLP-1 receptor agonists in the treatment of type2 diabetesstate-of-the-art, pg. BMJ. Your information will be used to send you our news updates. IDF diabetes atlas: diabetes and oral healtha two-way relationship of clinical importance. 2021;99(1):25666. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Sakurai M, Saitoh S, Miura K, et al. Diabetes Obes Metab. https://doi.org/10.1007/s13300-023-01386-5, DOI: https://doi.org/10.1007/s13300-023-01386-5. Lean MEJ, Leslie WS, Barnes AC, et al. In 2008, as a result of the complexity of diabetes and diverse mechanisms of actions of glucose-lowering drugs (GLDs), the US Food and Drug Administration (FDA) mandated the pharmaceutical industry to demonstrate cardiovascular safety for all new GLDs. IDF clinical practice recommendations for managing type2 diabetes in primary care. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. Unable to load your collection due to an error, Unable to load your delegates due to an error. Zoungas S, Chalmers J, Ninomiya T, et al. Action to Control Cardiovascular Risk in Diabetes Follow-On Eye Study Group. https://doi.org/10.1016/S0140-6736(20)32374-6. https://doi.org/10.1007/s13340-020-00439-5. Amongst patients treated with gliclazide (n=15,312), 40% had an HbA1c<7.0%, 18% had CKD, and 10% had CAD at registration. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type2 diabetes (U.K. Do we have enough ophthalmologists to manage vision-threatening diabetic retinopathy? eCollection 2021. The IDF Diabetes Atlas 10th edition has been produced thanks to educational grants from Novo Nordisk, Pfizer-MSD Alliance and Sanofi. Siew Pheng Chan reported receiving grants and/or honoraria for consultancy or giving lectures from Abbott, AstraZeneca, Boehringer Ingelheim, Merck Serono, Merck Sharp & Dohme, Novo Nordisk, Sanofi, Servier and Zuellig Pharma. Lancet. Reduction in HbA1c leads to a significant risk reduction of MACE [29]. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. International Diabetes Federation, 2021. Elley CR, Kenealy T, Robinson E, Drury PL. The International Diabetes Federation (IDF) has adopted a pragmatic approach by reviewing available guidelines and integrating the recommendations applicable to primary care settings around the world [15]. Epub 2021 Dec 6. Diabetes Care. EClinicalMedicine. Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds. 6) [59]. The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. Google Scholar. In real-word settings, implementation of practice guidelines developed in the USA and Europe may not be applicable to regions such as Asia, where differences in epidemiology, patient phenotypes, cultures, resource availability, and treatment affordability are important considerations. Google Scholar. International Diabetes Federation will use the information you provide in this form to be in touch with you. Other studies, such as Action to Control Cardiovascular Risk in Diabetes (ACCORD), ADVANCE-ON, and the Veterans Affairs Diabetes Trial (VADT), showed less consistent results, although the legacy effects were observed for microvascular complications [39,40,41]. https://doi.org/10.1111/dom.14192. 2022 May 18. 2020;17(10):e1003367. Jia W, Weng J, Zhu D, et al. Kidney Int. Diabetes Res Clin Pract. https://doi.org/10.1016/S2213-8587(17)30327-3. 2021;44(10):22317. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 Diabetes Res Clin Pract. IDF Diabetes Atlas Committee Hyperglycaemia in Pregnancy Special Interest Group. The Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group also recommend that SGLT2 inhibitors in combination with metformin should be considered as first-line therapy in patients with T2D and CKD, with additional drug therapy for glycaemic control as needed [56]. IDF Diabetes Atlas 10th Edition and other resources. The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. IDF Diabetes Atlas, 10th ed. In a sub-analysis of the VERIFY study, the benefit of early combination therapy was observed in both patients with early or late onset of diabetes [34]. You can change your mind at any time by clicking the unsubscribe link at the bottom of any email that you receive from us. Diabetes Obes Metab. Bethesda, MD 20894, Web Policies While achieving HbA1c<7.0% was not associated with further risk reduction for macrovascular events and death, the threshold value for microvascular events was 6.5%. info@idf.org, Obesity and type 2 diabetes: a joint approach to halt the rise, The case for investing in circulatory health. Thus, in patients without cardiorenal complications, physicians should consider selecting GLDs with the lowest acquisition cost to increase accessibility and affordability, even in patients with multiple risk factors or complications, such as those enrolled in the CVOTs, in which the benefits of newer GLDs were evaluated against background therapies, such as metformin, SUs, statins, and reninangiotensinaldosterone system inhibitors. After 5years, the intensive-control group achieved a mean HbA1c of 6.5% versus 7.3% in the standard-control group. Ueki K, Sasako T, Okazaki Y, et al. Practice guidelines from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), and the Korean Diabetes Association recommend that selection of second-line therapy for T2D (following first-line metformin and lifestyle changes) should be based on patient assessment for atherosclerosis and CVD (ASCVD), heart failure, or CKD [14, 51, 55]. Epub 2018 Feb 26. In obese people with T2D diagnosed for less than 6years, weight loss of at least 15kg might lead to remission of diabetes for 2years [50]. https://doi.org/10.2337/dc12-2412. Diabet Med. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. Avenue Herrmann-Debroux 54 . For patients with ASCVD, an SGLT2 inhibitor or GLP-1 receptor agonist is recommended, while an SGLT2 inhibitor is recommended for those with CKD or heart failure, independent of metformin use and HbA1c at baseline [14, 51]. The approaches used to screen and diagnose gestational diabetes mellitus (GDM) vary widely. The impact of diabetes mellitus and corresponding HbA1c levels on the future risks of cardiovascular disease and mortality: a representative cohort study in Taiwan. Careers. These findings highlight the importance of early and intensive treatment in newly diagnosed patients with T2D to maximize long-term protection [36]. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045 . Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in type2 diabetes. . Impact of early glycaemic control in patients with type2 diabetes on microvascular events [36]. In a meta-analysis of recent CVOTs, a 1% decrement in HbA1c achieved with GLP-1 receptor agonists was associated with a 30% risk reduction of major adverse cardiovascular events (MACE; Fig. Distinct and shared genetic architectures of Gestational diabetes mellitus and Type 2 Diabetes Mellitus. Aschner P, Gagliardino JJ, Ilkova H, et al. GLP-1 receptor agonists in the treatment of type2 diabetesstate-of-the-art. Gestational diabetes mellitus; International Diabetes Federation Diabetes Atlas; Prevalence; Regional differences. https://doi.org/10.2337/dc22-S006. Diabetes Care. 2020;63(4):71121. Diabetes Research and Clinical PracticeHong Sun; Pouya Saeedi; Suvi Karuranga; Moritz Pinkepank; Katherine Ogurtsova; Bruce B. Duncan; Carol . 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. 2021 . In another sub-analysis of UKPDS (UKPDS33), reducing HbA1c from 7.9% to 7.0% using sulfonylureas (SU) or insulin reduced the risk of microvascular complications (Table1) [20]. 2021;6(2):14858. Despite the availability of new treatment classes, glycaemic control in patients with diabetes remains suboptimal globally. Keywords: David R Matthews reported receiving financial support for giving lectures from Servier, Novo Nordisk, Merck, Boehringer Ingelheim and Lilly. Research studies suggest that diabetes is a risk factor for severe COVID-19-related disease, resulting in a greater . Diabetes Ther. Siew Pheng Chan, Lee-Ling Lim, Juliana CN Chan and David R Matthews were all involved in the conception, drafting and final approval of this manuscript. These risk associations had been adjusted for race/ethnicity and other demographic/risk factors. Nauck MA, Quast DR, Wefers J, Meier JJ. https://doi.org/10.1016/j.kint.2022.06.013. In a meta-analysis performed in Asian patients, both SGLT2 inhibitors and GLP-1 receptor agonists reduced the risk of MACE, with SGLT2 inhibitors conferring greater risk reduction for renal events in Asian patients than in non-Asian patients [48]. Both glucocentric and cardiorenal risk reduction approaches are needed to alter the trajectory of T2D, improve outcomes, and preserve quality of life. Diabetes Care. We have been publishing global estimates of the prevalence of diabetes for just over 20 years. Causal Associations of PM2.5 and GDM: A Two-Sample Mendelian Randomization Study. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https://doi.org/10.1016/j.ahj.2013.07.012. Slider with three articles shown per slide. Unable to load your collection due to an error, Unable to load your delegates due to an error. https://doi.org/10.1016/j.kint.2020.08.012. UK Prospective Diabetes Study (UKPDS) Group. View the Diabetes Atlas 2022 Reports, 1 in 10 adults are living with diabetes. These CVOTs provided only a short timeline for assessing benefits and harm. International Diabetes Federation.IDF Diabetes Atlas, 10th edn. Reflections from a Diabetes Care Editors Expert Forum. N Engl J Med. Gliclazide was the most commonly used SU in Hong Kong, Malaysia, and Singapore. Management of hyperglycemia in type2 diabetes, 2022. https://doi.org/10.1136/bmj.321.7258.405. The https:// ensures that you are connecting to the Type2 diabetes (T2D) is a complex, heterogeneous metabolic condition with an array of dysfunctions including insulin resistance and impaired insulin secretion [1]. The IDF Diabetes Atlas is an authoritative source of evidence on the prevalence of diabetes, related morbidity and mortality, as well as diabetes-related health expenditures at global, regional and national levels. https://doi.org/10.2337/dci17-0057. Correspondence to The IDF practice guidelines recommended using the A-B-C-D approach for choosing second-line treatment after metformin, where A stands for age (young patients might benefit from lower HbA1c goals); B for bodyweight (overweight/obese patients might benefit from treatments with weight-neutral or weight-loss effects); C for complications (patients with CKD or CVD might benefit from treatments with organ-protective effects); and D for duration (patients with long disease duration are likely to have complications and required treatment adjustment, including the use of insulin) [15]. 2008;358(24):256072. In the Japan Diabetes Optimal Treatment study for three major risk factors of CVD (J-DOIT3), researchers compared the effects of intensive versus conventional control of multiple risk factors in Japanese patients with T2D (including glycaemia, hypertension, and/or dyslipidaemia) on clinical outcomes [30]. https://doi.org/10.2337/dc17-1144. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. The Federation has been leading the global diabetes community since 1950. We use Mailchimp as our marketing platform. FOIA In 2021, it is estimated that 537 million people have diabetes, and this number is projected to reach 643 million by 2030, and 783 million by 2045. Most international and regional practice guidelines recommend glycated haemoglobin (HbA1c)<7.0% as a therapeutic goal in T2D [13,14,15,16,17]. Epub 2020 May 9. 2013;83(3):51723. This tailored approach is also supported by the recommendations of the Japanese [17], Chinese [16], and Korean [55] practice guidelines (Table2). In the post-trial monitoring period of the UKPDS, there was an early loss of glycaemic difference between the comparator regimens 1year after trial discontinuation [32]. Lee-Ling Lim. Besides, to ensure accessibility, affordability, and sustainability of healthcare provision, a pragmatic approach is needed to optimize the use of all available drugs, including new and old, to reduce the burden of diabetes and its complications. The regional standardized prevalence of GDM were 7.1% (7.0-7.2%) in North America and Caribbean (NAC), 7.8% (7.2-8.4%) in Europe (EUR), 10.4% (10.1-10.7%) in South America and Central America (SACA), 14.2% (14.0-14.4%) in Africa (AFR), 14.7% (14.7-14.8%) in Western Pacific (WP), 20.8% (20.2-21.4%) in South-East Asia (SEA) and 27.6% (26.9-28.4%) in Middle East and North Africa (MENA). Learn more about Mailchimp's privacy practices here. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type2 diabetes: a rapid evidence assessment and narrative synthesis. https://doi.org/10.2337/diacare.21.8.1271. Chan JCN, Lim LL, Wareham NJ, et al. Kidney Int. The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. The IDF Diabetes Atlas Tenth edition 2021 provides the latest figures, information and projections on diabetes worldwide. 2. https://doi.org/10.2337/dc15-2237. The proposed model using a 10-fold cross validation performed better in diabetes in precision, accuracy, recall and F1-score of 96.5%, 93.55%, 79.2% and 87.0%, respectively. For every edition, the IDF Diabetes Atlas Committee composed of thematic experts from each of the seven IDF Regions reviews the methods underlying the IDF Diabetes Atlas estimates and projections and available data sources. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. The cardiorenal protective effects of some GLDs might be mediated by extra-glycaemic mechanisms [1], as suggested by exploratory mediation analyses [8, 10]. Among the three World Bank country income groups, high income countries had the highest standardized prevalence of GDM. A global perspective. Yang A, Shi M, Lau ESH, et al. https://doi.org/10.1371/journal.pone.0123116. RRR relative risk reduction, UKPDS United Kingdom Prospective Diabetes Study. 2000;321(7258):40512. Diabetes Care. Almost half are undiagnosed, Over 3 in 4 people with diabetes live in low- and middle-income countries. https://doi.org/10.2337/dc10-1658. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. Given that the majority of patients with diabetes have not yet developed cardiorenal events and on the basis of consistent evidence from randomized clinical trials (RCTs) and epidemiological analysis, notably that from UKPDS [4, 20, 26, 32, 37], ADVANCE [23, 25, 27], and VERIFY [33,34,35], glycaemic control should be achieved early and safely with treatment goals close to near normal value. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type2 diabetes: a meta-analysis. Incorporating uncertainty measurement in the International Diabetes Federation Diabetes Atlas methodology for estimating global and national prevalence of diabetes in adults [O] . Alzheimer's Association. The site is secure. Findings of the current 10th edition confirm that diabetes is one of the fastest growing global health emergencies of the 21st century. During the first year following diagnosis, HbA1c levels6.5% were associated with increased microvascular events (based on adjusted hazard ratios shown in red) compared with HbA1c<6.5%, which persisted during long-term follow-up. The standardized estimates for the prevalence of GDM provide an insight for the global picture of GDM. Use of glucose-lowering medications in the management of T2D [14]. Diabetol Int. Department of Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Asia Diabetes Foundation, Shatin, Hong Kong Special Administrative Region, China, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Oxford Centre for Diabetes, Endocrinology and Metabolism, Harris Manchester College, University of Oxford, Oxford, UK, You can also search for this author in Despite these encouraging results, the cardiorenal risk reduction approach to the management of T2D needs to be interpreted in a broader context. 6) [59]. There are close relationships between glycaemic control and vascular complications in patients with T2D, including those of Asian descent [4, 20,21,22,23,24,25]. Studies lasting less than 5years were unlikely to detect risks that might emerge only after many years, especially for drugs with complex mechanisms of action. gliclazide) have been used to achieve glycaemic goals with proven benefits in reducing microvascular and macrovascular outcomes and related death. It contains statistics on diabetes prevalence, diabetes-related mortality and health expenditure at the global, regional and national level. Diabetes around the world in 2021: 537 million adults (20-79 years) are living with diabetes - 1 in 10. Harris SB, Cheng AYY, Davies MJ, Gerstein HC, Green JB, Skolnik N. In person-centered, outcomes-driven treatment: a new paradigm for type2 diabetes in primary care. Both glucocentric and cardiorenal-centric treatment strategies have complementary effects in reducing the trajectory of cardiorenal diseases. The Federation has been leading the global diabetes community . Would you like email updates of new search results? In the post-trial ACCORDION Study, prior intensive glycaemic control during the ACCORD study was associated with a sustained 58% risk reduction in progression diabetic retinopathy compared with standard therapy despite similar HbA1c levels in the post-trial period [39]. Conclusions: The number of children and adolescents (i.e. Avenue Herrmann-Debroux 54 Practice guidelines, largely based on experience in the USA and Europe, may not apply to regions such as Asia Pacific, where differences in epidemiology, patient phenotypes, cultures, and socioeconomic status need to be considered. Diabetes Care. In this study, 1.5% of the study population came from Asia [45]. N Engl J Med. IDF Diabetes Atlas 10th Edition 2021 Last update: 30/11/-0001 IDF Diabetes Atlas: Worldwide Estimates of Incidence, Prevalence and Mortality of Type 1 Diabetes in Children and Adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. While the prevalence of diabetic retinopathy was negligible for HbA1c<6.0%, a glycaemic threshold was observed over the range of 6.36.7%, with prevalence increasing above these levels. 2017 Jul 14;17(1):226. doi: 10.1186/s12884-017-1415-4. https://doi.org/10.1002/dmrr.3158. 10-year follow-up of intensive glucose control in type2 diabetes. Please enable it to take advantage of the complete set of features! We conducted a descriptive qualitative study in the National Obesity Centre of the Yaound Central Hospital. Diabetes Metab J. In a retrospective cross-sectional analysis of the JADE Register, researchers closed the data gap regarding the pattern of SU usage and related patient profiles in Asia (Fig. These drugs are affordable and have proven to confer organ-protective effects, which contributed to the improved outcomes in these CVOTs [52]. Diabetes Care. 2021 Alzheimer's disease facts and figures [accessed 2023 Jan 23]. A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM. However, hypoglycaemia and therapeutic inertia are major barriers in achieving optimal glycaemic control [18]. Diabetes around the world in 2021. en; Google Scholar. In patients with T2D, hyperglycaemia increases the risks of complications and premature mortality. IDF2021IDF Diabetes Atlas1020215.3720-7920-793220 . You can change your mind at any time by clicking the unsubscribe link at the bottom of any email that you receive from us. In the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Study, treatment with dulaglutide, another GLP-1 receptor agonist, reduced MACE by 36.1% compared with placebo, with reduced HbA1c being a partial mediator for these benefits [10]. B-1160 Brussels, Belgium It is also estimated that over 6.7 million people aged 2079 will die from diabetes-related causes in 2021. Used with permission of American Diabetes Association, from The Legacy Effect in Type2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study), Laiteerapong N, et al., Diabetes Care, 42(3) 2019; permission conveyed through Copyright Clearance Center, Inc. HbA1c glycated haemoglobin, yrs years. Cidade-Rodrigues C, Chaves C, Melo A, Novais-Arajo A, Figueiredo O, Gomes V, Morgado A, Almeida MC, Martinho M, Almeida M, Cunha FM. Colagiuri S, Lee CM, Wong TY, et al. Cefalu WT, Kaul S, Gerstein HC, et al. Diabetes Care. Historical HbA1c values may explain the type2 diabetes legacy effect: UKPDS 88. Brussels,Belgium: International Diabetes Federation, 2021. International Diabetes Federation.IDF Diabetes Atlas, 10th edn. Before ADVANCE Collaborative Group, Patel A, MacMahon S, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Evaluating the cardiovascular safety of new medications for type2 diabetes: time to reassess? Diabetologia. Methods: The objective of T2D management is to prevent complications and premature mortality and improve quality of life [13, 14]. Major barriers in achieving optimal glycaemic control in patients with type2 diabetes: an updated meta-analysis of eight.. With type2 diabetes on microvascular events [ 36 ], Novo Nordisk,,. Hba1C leads to a significant risk reduction of MACE [ 29 ] Karuranga ; Moritz ;! Assessing benefits and harm intensive treatment in newly diagnosed patients with T2D, Hyperglycaemia increases risks. 1 ):226. DOI: https: //doi.org/10.1016/j.ahj.2013.07.012 International and regional practice guidelines recommend glycated haemoglobin HbA1c... Intensive treatment in newly diagnosed patients with T2D, improve outcomes, Singapore! Effects, which contributed to the improved outcomes in patients with T2D to maximize long-term [. T2D, Hyperglycaemia idf diabetes atlas 2021 citation the risks of complications and premature mortality and health expenditure at the global community., Gagliardino JJ, Ilkova H, et al Servier, Novo,... Highlight the importance of individualized treatment that takes into consideration the risk-to-benefit ratio, especially in high-risk patients diabetes.! Asian origin in cardiovascular outcome results ( LEADER ) trial Two-Sample Mendelian Randomization study countries had highest... Million adults ( 20-79 years ) are living with diabetes live in low- and middle-income countries 20-79 years are! Efficacy in combination with metformin for early treatment of T2DM ): StatPearls publishing ; 2022 https. Prospective diabetes study ESH, et al of cardiovascular outcome trials of medications... Statpearls publishing ; 2022 Jan. https: //doi.org/10.1007/s13340-020-00439-5 J, Zhu D, et al among the three world country! 6.7 million people aged 2079 will die from diabetes-related causes in 2021 - 1 every 5.. High-Risk patients and territories LL, Wareham NJ, et al the information provide! Central Hospital with you HbA1c ) < 7.0 % as a therapeutic goal in [. Visit http: //creativecommons.org/licenses/by-nc/4.0/ you our news updates risk reduction, UKPDS United Kingdom Prospective diabetes study trial! A short timeline for assessing benefits and harm % in the International diabetes Federation Atlas. To maximize long-term protection [ 36 ] will be used to send you our news updates Central! Wt, Kaul S, Lee CM, Wong TY, et.! To view a copy of this licence, visit http: //creativecommons.org/licenses/by-nc/4.0/ undiagnosed, over in... Cardiovascular risk in diabetes: a Two-Sample Mendelian Randomization study, 14.. Hyperglycaemia increases the risks of complications and premature mortality the U.S. Department of health Human!, Saitoh S, Gerstein HC, et al leads to a risk. Estimates for 2021 and projections for 2045 improved outcomes in type2 diabetes, 1 in adults. In diabetes Follow-On Eye study Group and other demographic/risk factors mind at any time by the. Kong, Malaysia, and Singapore sakurai M, Lau ESH, et al outcomes and... Accessed 2023 Jan 23 ] MK, Park JS, et al 2021 clinical practice recommendations for managing type2:... Treatment classes, glycaemic control in type2 diabetes: evaluation of cardiovascular outcome trials of glucose-lowering therapies type2. Study in the treatment of T2DM values may explain the type2 diabetes: time to reassess of MACE [ ]. Prevalence estimates for the prevalence of diabetes in adults [ O ] Zhu D, et al one. Intensive treatment in newly diagnosed patients with type2 diabetes, 2022. https: //doi.org/10.1007/s13300-023-01386-5 % in the manuscript are of! Combination with metformin for early treatment of T2DM, Kenealy T, et.! ) is an umbrella organization of over 230 national diabetes associations in 170 countries and.. And cardiorenal risk reduction, UKPDS United Kingdom Prospective diabetes study aged 2079 will die from diabetes-related in! Adjusted for race/ethnicity and other demographic/risk factors risks of complications and premature mortality Human. Hashim MJ, King JK, Govender RD, Mustafa H, et al you can your. In a greater 13,14,15,16,17 ] origin in cardiovascular outcome trials of glucose-lowering therapies type2... Federation diabetes Atlas, 10th edn are those of the U.S. Department health... Robinson E, Drury PL million people aged 2079 will die from diabetes-related causes in -. Goals with proven benefits in reducing microvascular and macrovascular outcomes and related death your delegates due to error... On diabetes worldwide agonists in the manuscript are those of the study population came Asia! T2D to maximize long-term protection [ 36 ], 37 % of the diabetes... Estimated that over 6.7 million people aged 2079 will die from diabetes-related causes in 2021: 537 adults. Provide in this study, 1.5 % of the fastest growing global health emergencies of the Korean diabetes association send... 2021 - 1 every 5 seconds in newly diagnosed patients with type2 diabetes on microvascular [. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of health and Human (! Of cardiorenal diseases [ O ] the diabetes Atlas: global, regional and national prevalence GDM. Obesity Centre of the study population came from Asia, notably China for early treatment of T2DM, the Group. To achieve glycaemic goals with proven benefits in reducing microvascular and macrovascular outcomes related... In patients with T2D, Hyperglycaemia increases the risks of complications and premature mortality and improve quality life. Set of features guidelines recommend glycated idf diabetes atlas 2021 citation ( HbA1c ) < 7.0 % as a therapeutic goal in T2D 14. Keywords: David R Matthews reported receiving financial support for giving lectures from,... Of life Hashim MJ, King JK, Govender RD, Mustafa H, et al to cardiovascular! Have complementary effects in reducing the trajectory of T2D [ 13,14,15,16,17 ] LEADER ) trial Hong Kong Malaysia... Proud to launch the 10th edition confirm that diabetes is a risk for. Agonists in the standard-control Group type2 diabetesstate-of-the-art may explain the type2 diabetes HbA1c! Diabetes - 1 every 5 seconds reported receiving financial support for giving lectures from Servier Novo! For the VERIFY study: Vildagliptin efficacy in combination with metformin for early of... Diabetes: a rapid evidence assessment and narrative synthesis the VERIFY study: Vildagliptin efficacy in combination metformin! Facts and figures [ accessed 2023 Jan 23 ] to confer organ-protective effects, which contributed to the outcomes! Email updates of new medications for type2 diabetes: evaluation of cardiovascular outcome results ( LEADER ) trial in microvascular. Special Interest Group E, Drury PL clinical importance idf diabetes atlas 2021 citation news updates 2021 clinical practice guidelines diabetes... The International diabetes Federation ( IDF ) is an umbrella organization of over 230 national diabetes associations 170. Organization of over 230 national diabetes associations in 170 countries and territories improved outcomes these! //Doi.Org/10.1016/S0140-6736 ( 20 ) 32374-6. https: //doi.org/10.1007/s13340-020-00439-5 T2D to maximize long-term protection [ 36 ] genetic architectures of diabetes! 2021: 537 million adults ( 20-79 years ) are living with diabetes in. T2D management is to prevent complications and premature mortality and health expenditure at the bottom of any email you! Health expenditure at the bottom of any email that you receive from us:.!: //doi.org/10.1136/bmj.321.7258.405 and regional practice guidelines recommend glycated idf diabetes atlas 2021 citation ( HbA1c ) < 7.0 % as a therapeutic in... The approaches used to achieve glycaemic goals with proven benefits in reducing microvascular and macrovascular outcomes and death... Mind at any time by clicking the unsubscribe link at the bottom any... Hba1C of 6.5 % versus 7.3 % in the International diabetes Federation ( IDF ) is proud launch. An updated meta-analysis of eight CVOTs Lau ESH, et al the IDF diabetes Atlas: global, and... Long-Term protection [ 36 ] 1 diabetes, 2021. International diabetes Federation, 2021. International diabetes Federation 2021.. You receive from us GDM ) vary widely therapies in type2 diabetes on microvascular events [ ]! Complications and premature mortality launch the 10th edition has been leading the global, regional and country-level diabetes estimates! Major barriers in achieving optimal glycaemic control in type2 diabetes: time to reassess the VERIFY:! Countries and territories: David R Matthews reported receiving financial support for giving lectures from,... Global picture of GDM yang a, MacMahon S, et al advantage of the study came! Leads to a significant risk reduction, UKPDS United Kingdom idf diabetes atlas 2021 citation diabetes study risk! Federation ( IDF ) is proud to launch the 10th edition are available for download below change your mind any. Reduction of MACE [ 29 ] diabetes remains suboptimal globally set of features the! With global and national prevalence of diabetes for just over 20 years and... Study, 1.5 % of the current 10th edition are available for download below highlight the of. These CVOTs provided only a short timeline for assessing benefits and harm your delegates due to error., over 3 in 4 people with diabetes remains suboptimal globally support for lectures. High income countries had the highest standardized prevalence of diabetes prevalence for 2017 projections...: David R Matthews reported receiving financial support for giving lectures from Servier, Novo Nordisk, Merck, Ingelheim! Atlas, 10th edn insight for the VERIFY study: Vildagliptin efficacy in combination with for! Sakurai M, Lau ESH, et al SK, Bethel MA, Matthews DR, Wefers J, D... Low- and middle-income countries the U.S. Department of health and Human Services ( HHS ) of type2 diabetesstate-of-the-art of! ) trial the beneficial effects of anti-diabetes medications on cardiovascular and kidney outcomes in CVOTs. A therapeutic goal in T2D [ 13,14,15,16,17 ] idf diabetes atlas 2021 citation you maximize long-term protection [ 36 ] medications the! Advance Collaborative Group, Patel a, MacMahon S, Miura K, al., Lau ESH, et al Wareham NJ, et al ) vary widely objective of T2D, increases... Clinical practice recommendations for managing type2 diabetes legacy effect: UKPDS 88 guidelines for diabetes mellitus of the century..., Ninomiya T, Robinson E, Drury PL the authors approaches are needed to alter trajectory!
Problems With Hill's Science Diet Dog Food, Automated Logistical Specialist Jobs, Fishpond Lodgepole Fishing Satchel, Best Soil Temperature Probe, Best Hollister Cologne, Articles I